Sputnik V – “the first registered COVID-19 vaccine” [to 28 Nov 2020]

Milestones :: Perspectives :: Research

 

Editor’s Note:
To better present a global view of COVID-19 vaccine development, regulatory review, procurement and deployment, we will present headlines from this site – which provides as its contact point the Russian Direct Investment Fund [RDIF].

Sputnik V – “the first registered COVID-19 vaccine” [to 28 Nov 2020]
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
RDIF and Hetero agree to produce over 100 million doses of the Sputnik V vaccine in India
Press release, 27.11.2020

The cost of one dose of the Sputnik V vaccine will be less than $10 for international markets
Press release, 24.11.2020

Second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose; vaccine efficacy is over 95% 42 days after the first dose
Press release, 24.11.2020